Permanent pacemaker implantation in unexplained syncope patients with electrophysiology study-proven atrioventricular node disease
Autor: | Kostas Gatzoulis, Kostas Tsioufis, Petros Arsenos, Ioannis Doundoulakis, C-K Antoniou, Polychronis E. Dilaveris, Stergios Soulaidopoulos, Skevos Sideris, Athanasios Kordalis, Dimitris Tsiachris, A Laina |
---|---|
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
Presyncope medicine.diagnostic_test biology business.industry Syncope (genus) Disease medicine.disease biology.organism_classification Atrioventricular node law.invention Electrophysiology study medicine.anatomical_structure law Physiology (medical) Internal medicine medicine Cardiology Artificial cardiac pacemaker Permanent pacemaker Cardiology and Cardiovascular Medicine business |
Zdroj: | EP Europace. 23 |
ISSN: | 1532-2092 1099-5129 |
DOI: | 10.1093/europace/euab116.318 |
Popis: | Funding Acknowledgements Type of funding sources: None. Background/Introduction: Syncope, whose cause is unknown after an initial assessment, has an uncertain prognosis. It is critical to identify patients at highest risk who may require a pacemaker and to identify the cause of recurrent syncope to prescribe proper therapy Purpose Aim of this study was to evaluate the effect of permanent pacing on the incidence of syncope in patients with unexplained syncope and electrophysiology study-proven atrioventricular node disease. Methods This was an observational study based on a prospective registry of 236 consecutive patients (60.20 ± 18.66 years, 63.1% male, 60.04 ± 9.50 bpm) presenting with recurrent unexplained syncope attacks admitted to our hospital for invasive electrophysiology study (EPS). Τhe implantation of a permanent antibradycardia pacemaker (ABP) was offered to all patients according to the results of the EPS. 135 patients received the ABP, while 101 denied. Results The mean of reported syncope episodes was 1.97 ± 1.10 (or presyncope 2.17 ± 1.50) before they were referred for a combined EP guided diagnostic and therapeutic approach. Over a mean follow-up of approximately 4 years (49.19 ± 29.58 months), the primary outcome event (syncope) occurred in 31 of 236 patients (13.1%), 6 of 135 (4.4%) in the ABP group as compared to 25 of 101 (24.8%) in the no pacemaker group (p < 0.001). Conclusion Among patients with a history of unexplained syncope, a set of positivity criteria for the presence of EPS defined atrioventricular node disease, identifies a subset of patients who will benefit from permanent pacing. |
Databáze: | OpenAIRE |
Externí odkaz: |